Shares of Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $17.72 and traded as high as $18.15. Pro-Dex shares last traded at $18.15, with a volume of 4,020 shares.
Analyst Ratings Changes
Separately, StockNews.com cut shares of Pro-Dex from a "strong-buy" rating to a "buy" rating in a report on Tuesday, February 20th.
Read Our Latest Stock Analysis on Pro-Dex
Pro-Dex Stock Performance
The company has a fifty day moving average of $17.91 and a two-hundred day moving average of $17.72. The firm has a market capitalization of $63.58 million, a price-to-earnings ratio of 24.37 and a beta of 0.60. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.16 and a current ratio of 3.66.
Pro-Dex (NASDAQ:PDEX - Get Free Report) last released its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $0.14 EPS for the quarter. The business had revenue of $12.59 million for the quarter. Pro-Dex had a net margin of 5.59% and a return on equity of 8.97%.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of PDEX. Dimensional Fund Advisors LP boosted its position in shares of Pro-Dex by 1.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 58,751 shares of the medical instruments supplier's stock worth $920,000 after acquiring an additional 625 shares in the last quarter. State Street Corp increased its stake in shares of Pro-Dex by 5.8% in the 1st quarter. State Street Corp now owns 11,923 shares of the medical instruments supplier's stock valued at $197,000 after purchasing an additional 650 shares during the last quarter. Northern Trust Corp increased its stake in shares of Pro-Dex by 4.1% in the 2nd quarter. Northern Trust Corp now owns 19,735 shares of the medical instruments supplier's stock valued at $377,000 after purchasing an additional 776 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Pro-Dex by 345.6% during the 3rd quarter. Tower Research Capital LLC TRC now owns 2,687 shares of the medical instruments supplier's stock worth $48,000 after buying an additional 2,084 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Pro-Dex by 1.8% during the 3rd quarter. Vanguard Group Inc. now owns 121,196 shares of the medical instruments supplier's stock worth $1,903,000 after buying an additional 2,181 shares during the last quarter. Institutional investors own 15.28% of the company's stock.
About Pro-Dex
(
Get Free Report)
Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
Read More
Before you consider Pro-Dex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pro-Dex wasn't on the list.
While Pro-Dex currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
